New pill could tame lung inflammation in sarcoidosis

NCT ID NCT06205121

Recruiting now Disease control Sponsor: Molecure S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This Phase 2 trial tests OATD-01, an oral drug that blocks a protein called chitinase-1, in 96 people with active pulmonary sarcoidosis. Participants take the drug or a placebo for 12 weeks to see if it reduces lung inflammation measured by PET scans. The goal is to find a new treatment option for this chronic lung condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OATD-01 (an oral drug that blocks chitinase-1, a protein involved in inflammation)
What this could lead to: If successful, this could point toward a new treatment option for people with active pulmonary sarcoidosis, potentially reducing lung inflammation without needing long-term steroids.
What could go wrong: This is an early Phase 2 trial with only 96 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary sarcoidosis sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY SARCOIDOSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Molecure Investigative Site
WITHDRAWN

Birmingham, Alabama, 35209, United States
Molecure Investigative Site
WITHDRAWN

Kansas City, Kansas, 66062, United States
Molecure Investigative Site
RECRUITING

Baltimore, Maryland, 21224, United States
Molecure Investigative Site
WITHDRAWN

Rochester, Minnesota, 55905, United States
Molecure Investigative Site
RECRUITING

Cleveland, Ohio, 44195, United States
Molecure Investigative Site
RECRUITING

Philadelphia, Pennsylvania, 19140, United States
Molecure Investigative Site
RECRUITING

Charleston, South Carolina, 29425, United States
Molecure Investigative Site
WITHDRAWN

Vejle, 7100, Denmark
Molecure Investigative Site
WITHDRAWN

Bobigny, 93000, France
Molecure Investigative Site
RECRUITING

Montpellier, 34295, France
Molecure Investigative Site
RECRUITING

Paris, 75013, France
Molecure Investigative Site
RECRUITING

Paris, 75015, France
Molecure Investigative Site
RECRUITING

Essen, 45239, Germany
Molecure Investigative Site
RECRUITING

Freiburg im Breisgau, 79106, Germany
Molecure Investigative Site
RECRUITING

Mainz-GE, 55131, Germany
Molecure Investigative Site
WITHDRAWN

Corfu, 49100, Greece
Molecure Investigative Site
RECRUITING

Heraklion, 71500, Greece
Molecure Investigative Site
RECRUITING

Pátrai, 26500, Greece
Molecure Investigative Site
RECRUITING

Thessaloniki, 57010, Greece
Molecure Investigative Site
RECRUITING

Nieuwegein, 3435 CM, Netherlands
Molecure Investigative Site
RECRUITING

Rotterdam, 3015 GD, Netherlands
Molecure Investigative Site
RECRUITING

Bergen, 5009, Norway
Molecure Investigative Site
RECRUITING

Oslo, 1478, Norway
Molecure Investigative Site
RECRUITING

Birmingham, B15 2GW, United Kingdom
Molecure Investigative Site
WITHDRAWN

Cambridge, CB2 0AY, United Kingdom
Molecure Investigative Site
RECRUITING

Edinburgh, EH16 4SA, United Kingdom
Molecure Investigative Site
RECRUITING

London, SE5 9RS, United Kingdom
Molecure Investigative Site
RECRUITING

London, SW3 6JY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.